Joel S Freundlich
Overview
Explore the profile of Joel S Freundlich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
2186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lepori I, Liu Z, Evbarunegbe N, Feng S, Brown T, Mane K, et al.
bioRxiv
. 2025 Mar;
PMID: 40060676
Tuberculosis (TB), caused by (Mtb), is the deadliest single-agent infection worldwide. Current antibiotic treatment for TB takes a minimum of four months, underscoring the need for better therapeutics. The unique...
2.
Sharma P, Jiang Q, Li S, Ocke E, Tsotetsi K, Sukheja P, et al.
J Med Chem
. 2025 Mar;
68(5):5774-5803.
PMID: 40035499
A dire need exists for novel drugs to treat infection. In an effort to build on our early efforts targeting the MenG enzyme within the menaquinone biosynthetic pathway, we have...
3.
Warapande V, Meng F, Bozan A, Graff D, Fromer J, Mughal K, et al.
bioRxiv
. 2025 Feb;
PMID: 39974961
Drug discovery is inherently challenged by a multiple criteria decision making problem. The arduous path from hit discovery through lead optimization and preclinical candidate selection necessitates the evolution of a...
4.
Hong S, Resnick S, Iketani S, Cha J, Albert B, Fazekas C, et al.
Mol Syst Biol
. 2025 Jan;
21(2):158-172.
PMID: 39762652
With current treatments addressing only a fraction of pathogens and new viral threats constantly evolving, there is a critical need to expand our existing therapeutic arsenal. To speed the rate...
5.
Pederick J, Vandborg B, George A, Bovermann H, Boyd J, Freundlich J, et al.
ACS Infect Dis
. 2024 Dec;
11(1):238-248.
PMID: 39705018
The pathway of bacterial cysteine biosynthesis is gaining traction for the development of antibiotic adjuvants. Bacterial cysteine biosynthesis is generally facilitated by two enzymes possessing -acetyl-l-serine sulfhydrylases (OASS), CysK and...
6.
Pederick J, Vandborg B, George A, Bovermann H, Boyd J, Freundlich J, et al.
bioRxiv
. 2024 Sep;
PMID: 39345565
Author Summary: There is increasing interest in the investigation of non-essential pathways including bacterial cysteine metabolism for developing antibiotic adjuvants. Within this pathway the O-acetyl-ʟ-serine sulfhydrylase (OASS) enzymes CysK and...
7.
Chen X, Arun B, Nino-Meza O, Sarhan M, Singh M, Jeon B, et al.
Nat Commun
. 2024 Aug;
15(1):6657.
PMID: 39143055
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized...
8.
Chain C, Sheehan J, Xu X, Ghaffari S, Godbole A, Kim H, et al.
Nat Microbiol
. 2024 Apr;
9(5):1207-1219.
PMID: 38594311
Pseudomonas aeruginosa is a leading cause of hospital-acquired infections for which the development of antibiotics is urgently needed. Unlike most enteric bacteria, P. aeruginosa lacks enzymes required to scavenge exogenous...
9.
Gallardo-Macias R, Russo R, Sherwood M, Jaskowski M, Nasser W, Sharma P, et al.
J Med Chem
. 2024 Jan;
67(2):1384-1392.
PMID: 38225186
Hospital-acquired infections, caused by ESKAPE bacteria, are a challenging global public health concern, in part due to the emergence of drug-resistant strains. While profiling a diverse set of compounds for...
10.
Tucker E, Ruiz-Bedoya C, Mota F, Erice C, Kim J, De Jesus P, et al.
Int J Antimicrob Agents
. 2023 Dec;
63(1):107048.
PMID: 38061419
Tuberculous meningitis (TB meningitis) is the most devastating form of tuberculosis (TB) and there is a critical need to optimize treatment. Linezolid is approved for multidrug resistant TB and has...